NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
Study sponsor: Glaukos Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-02-07Actual
Enrollment · participants35Actual
Source updated2025-07-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.